שווי כולל של החברה: Trevi Corp (TRVI)

Trevi Therapeutics (TRVI) specializes in developing therapeutic agents to combat chronic cough. This price chart reflects an Enterprise Value of 1608.00, while the company lacks stable revenue and relies on external funding. High scalability potential is ensured by outsourcing production to contractors following IP registration. In the future, patents will enable the company to establish premium pricing.

Enterprise Value determines the total buyout cost of a business by combining market capitalization with net debt. By analyzing the indicative Enterprise Value level, an investor sees the real price of the asset net of liquid assets. This metric is sensitive to debt load and cash volume. For Trevi Therapeutics (TRVI), this figure reflects the value of the infrastructure, including scalable capacities for the production of neuro-drugs. The valuation confirms the investment attractiveness of the company's production potential.